SLC5A2 and breast cancer: A recent pooled analysis of twenty-one trials suggested that the increased risk of bladder and breast cancers observed in those treated with a specific SGLT-2 inhibitor (Dapagliflozin), might be the absence of detailed diagnosis prior to randomization rather than a causal relationship [149].